AcelRx Pharma (ACRX) Misses Q3 EPS by 2c
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
AcelRx Pharma (NASDAQ: ACRX) reported Q3 EPS of ($0.25), $0.02 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $2.89 million.
For earnings history and earnings-related data on AcelRx Pharma (ACRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Canadian Pacific Railway (CP) Tops Q4 EPS by CAD$0.23
- CVB Financial (CVBF) Tops Q4 EPS by 1c
- Wintrust Financial (WTFC) Tops Q4 EPS by 3c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!